{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["93"],"submitter":["Kiritopoulos D"],"pubmed_abstract":["<h4>Background and purpose</h4>Uncemented total hip arthroplasty (THA) is associated with periprosthetic bone loss. In a secondary outcome analysis from a randomized controlled trial, we studied whether denosumab can prevent loss of acetabular periprosthetic bone mineral density (pBMD) in patients who received a trabecular metal cup during uncemented THA.<h4>Patients and methods</h4>64 patients (aged 35-65 years) with unilateral osteoarthritis of the hip were randomized to 2 subcutaneous injections with denosumab or placebo, given 1-3 days post-surgery and 6 months post-surgery. Acetabular pBMD was measured in 5 regions of interest (ROIs) by dual-energy X-ray absorptiometry. Serum markers for bone metabolism were analyzed. Periprosthetic osteoblastic activity, measured as standardized upta"],"journal":["Acta orthopaedica"],"pagination":["709-720"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9450252"],"repository":["biostudies-literature"],"pubmed_title":["Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial."],"pmcid":["PMC9450252"],"pubmed_authors":["Mallmin H","Nystrom A","Kiritopoulos D","Sorensen J","Hailer NP","Ullmark G","Petren-Mallmin M","Milbrink J"],"additional_accession":[]},"is_claimable":false,"name":"Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial.","description":"<h4>Background and purpose</h4>Uncemented total hip arthroplasty (THA) is associated with periprosthetic bone loss. In a secondary outcome analysis from a randomized controlled trial, we studied whether denosumab can prevent loss of acetabular periprosthetic bone mineral density (pBMD) in patients who received a trabecular metal cup during uncemented THA.<h4>Patients and methods</h4>64 patients (aged 35-65 years) with unilateral osteoarthritis of the hip were randomized to 2 subcutaneous injections with denosumab or placebo, given 1-3 days post-surgery and 6 months post-surgery. Acetabular pBMD was measured in 5 regions of interest (ROIs) by dual-energy X-ray absorptiometry. Serum markers for bone metabolism were analyzed. Periprosthetic osteoblastic activity, measured as standardized upta","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-05-29T19:37:56.856Z","creation":"2024-11-06T07:07:32.932Z"},"accession":"S-EPMC9450252","cross_references":{"pubmed":["36069479"],"doi":["10.2340/17453674.2022.4537"]}}